The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Celtic Sea Portfolio

26 Mar 2015 07:00

RNS Number : 4944I
Fastnet Oil & Gas PLC
26 March 2015
 

26 March 2015

Fastnet Oil & Gas plc

("Fastnet" or the "Company")

 

Celtic Sea Portfolio

- New Licensing Option Awarded, Existing Licensing Options and Deep Kinsale Option Extended

 

Fastnet (AIM: FAST, ESM: FOI), the UK and Irish listed E&P company focused on near-term exploration and appraisal acreage in Morocco and the Celtic Sea, is pleased to announce an update on its Celtic Sea portfolio.

 

Highlights:

· Award of new operated licensing option named the Ventry Licensing Option ("Ventry") in the North Celtic Sea Basin.

o 100% working interest in the Ventry Licensing Option covering 996 km2 over blocks 55/13 and part of blocks 55/7, 55/8, 55/12, 55/17, 55/18 and 55/19.

o Contiguous with and extending westwards from the previously awarded Mizzen Licensing Option 12/3 and East Mizzen Licensing Option 13/3.

o 18-month licensing option with the opportunity to extend, which requires the reprocessing of existing 2D seismic data and various geologic studies.

· Extension of existing licensing options: 13/3 ("East Mizzen"), 12/5 ("Shanagarry") and 12/6 ("Block 49/13") for a period of 18 months each.

o Work commitments include the reprocessing of existing seismic data and various geological studies.

· Extension of the Deep Kinsale Option with PSE Kinsale Energy Limited ("Kinsale Energy"), until 31st December 2015 which allows the Company to continue farm-in discussions with potential partners.

 

Carol Law, CEO of Fastnet, commented:

"This announcement marks the successful conclusion of a significant investment of Company time, expertise and resources in securing our attractive Celtic Sea acreage position, a highly prospective area that is increasingly becoming the focus of industry interest. Modern seismic processing and geological techniques have allowed us to better understand the development of the petroleum systems in the area and build a portfolio of attractive low risk prospects and leads with excellent project economics even in the current oil pricing environment.

We are delighted to add the Ventry Licensing Option to our portfolio, and believe it offers significant extension acreage with potential material upside on the west side of the large Mizzen structural prospect. We believe the western side of this large uplift will contain similar prospective stratigraphic features to those mapped on our 2013 3D seismic on the eastern flank of the Mizzen high and, in the event of exploration success in Mizzen and East Mizzen, we will be well positioned with running room on the plays.

"The extensions on our three existing prospective licence areas allows us to carry out the agreed work programmes, currently underway, which are economical and fully funded. The extension of the deadline to exercise the Deep Kinsale Option allows us to continue our farm-out discussions and is enhanced by the recent farm-in by Kinsale Energy to Lansdowne's nearby SEL 4/07.

"While we continue to evaluate opportunities for M&A in the current market environment, the Celtic Sea is very important to Fastnet and we see the potential to deliver significant shareholder value through developing this portfolio and attracting partners to pursue exploration activities."

Award of New Licensing Option

The Company has been notified by the Irish Department of Communications, Energy and Natural Resources (the "Department") that it has been awarded licensing option 15/1 covering blocks 55/13 and part blocks 55/7, 55/8, 55/12, 55/17, 55/18 and 55/19 in the North Celtic Sea Basin.

The newly named Ventry Licensing Option is valid from 1 March 2015 to 31st August 2016. It covers an area of 996 km2, and is contiguous with and extending westwards from the Company's previously awarded Mizzen Licensing Option 12/3 and East Mizzen Licensing Option 13/3. Fastnet is the designated operator and has a 100% working interest in the Ventry Licensing Option. The licensing option covers a period of 18 months and requires the reprocessing of existing 2D seismic data and various geological studies. Upon completing the work programme, the Company has the opportunity to extend the licensing option by a further 18 months. The Ventry Licensing Option provides extension acreage with significant running room for multiple play types which have been clearly imaged on Fastnet's Mizzen 3D seismic data, which was acquired in 2013.

 

Extension of Existing Licensing Options

The Company has separately been notified by the Department that existing Licensing Options have been extended as follows:

· Licensing Option East Mizzen, extended for a further 18 months from 1st November 2014 to 30th April 2016.

· Licensing Option Shanagarry extended for a further 18 months from 1st June 2014 to 30th November 2015.

· Licensing Option 12/6 ("Block 49/13") extended 15th May 2014 until 14th November 2015.

In each of the Licensing Option work programmes associated with the three Licensing Options, the Company is required to reprocess existing seismic data and carry out various geological studies. The Company may elect to apply to convert these options to Exploration Licences following these extension periods.

Extension of Deep Kinsale Option

The Company is pleased to announce that it has agreed to extend its Exclusive Option agreement with Kinsale Energy until 31st December 2015. This extended period will allow the Company to continue farm-in discussions with potential partners. There are no changes to the exclusive option agreement from those previously announced on 14th August 2014.

The "Deep Kinsale Prospect" area extends from 4,000 feet subsea below the producing Kinsale Head gas field and is defined as the "Deep Kinsale Sub-Area" of Petroleum Lease No. 1 (see map of the area on the Company's website: www.fastnetoilandgas.com/go/operations/ireland).

An updated corporate presentation is now available for download on the Company website via the following link: http://www.fastnetoilandgas.com/investor-relations/presentations

For further information please contact:

 

Fastnet Oil & Gas plc

+353 (1) 644 0007

Carol Law, Chief Executive Officer

Cathal Friel, Non-Executive Chairman

Shore Capital

+44 (0) 20 7408 4090

Nomad

Bidhi Bhoma, Edward Mansfield

Corporate Broking

Jerry Keen

Davy

+353 (1) 679 6363

(ESM Adviser & Joint Broker)

John Frain, Anthony Farrell

Camarco

+44 (0) 20 3757 4980

Billy Clegg, Georgia Mann, Ellie Reid

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DRLDMGZFLKVGKZM
Date   Source Headline
4th Mar 202112:00 pmRNSAmryt Announces Record FY 2020 Results
25th Feb 20217:00 amRNSAmryt Supports Global Rare Disease Day 2021
24th Feb 20217:00 amGNWAmryt to Announce Q4 and FY 2020 Results on Thursday March 4, 2021
10th Feb 20217:00 amRNSAmryt to Present at SVB Leerink Conference
4th Feb 20217:00 amGNWAmryt and Medison Pharma Sign Multi-Regional Distribution Agreements in Canada and Israel
20th Jan 20217:00 amGNWAmryt Receives Reimbursement Approval from NICE for Myalepta® (metreleptin) in England and Wales
6th Jan 20217:00 amRNSAmryt to present at H.C Wainwright Conference
23rd Dec 20207:00 amGNWAmryt Granted Orphan Drug Designation by the FDA for AP103
17th Dec 20207:00 amGNWAmryt Receives Ministry of Health Reimbursement Approval for Lojuxta® (lomitapide) in Saudi Arabia
11th Dec 202010:00 amGNWHolding(s) in Company
9th Dec 20202:45 pmGNWHolding(s) in Company
9th Dec 20207:00 amGNWAmryt Group Receives Marketing Authorisation Approval for Lojuxta® in Brazil
8th Dec 20207:00 amGNWAmryt Announces $40m Private Placement with Leading Biotech Investors
5th Nov 202012:00 pmGNWAmryt Reports Record Q3 2020 Results - Raising FY 2020 Revenue Guidance
29th Oct 20207:00 amGNWAMRYT ANNOUNCES POSITIVE RESULTS FROM PHASE 3 TRIAL OF FILSUVEZ® IN EPIDERMOLYSIS BULLOSA
19th Oct 20207:00 amGNWAmryt and Swixx Sign Distribution Deal for Lojuxta
14th Oct 20207:00 amRNSAMRYT TO ANNOUNCE Q3 RESULTS ON NOVEMBER 5, 2020
14th Oct 20207:00 amGNWNotice of Results
12th Oct 202011:00 amGNWHolding(s) in Company
9th Oct 20207:00 amGNWVirtual Analyst & Investor Event - Tuesday November 3, 2020
8th Oct 20207:00 amGNWAMRYT TO PRESENT EASE TRIAL DATA BY LATE-BREAKING PRESENTATION AT EADV ON OCTOBER 31, 2020
1st Oct 20207:00 amGNWExercise of Options and Total Voting Rights
30th Sep 202012:30 pmGNWHolding(s) in Company
23rd Sep 20207:00 amRNSAMRYT SUPPORTS GLOBAL FH AWARENESS DAY
21st Sep 202011:00 amGNWExercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
15th Sep 20207:00 amRNSPOSITIVE OPINION ON AP103 ORPHAN DRUG DESIGNATION
9th Sep 20202:05 pmRNSSecond Price Monitoring Extn
9th Sep 20202:00 pmRNSPrice Monitoring Extension
9th Sep 20207:00 amRNSPOSITIVE TOP LINE RESULTS FROM PHASE 3 TRIAL IN EB
11th Aug 202011:09 amRNSCANCELLATION OF ADMISSION TO EURONEXT GROWTH
7th Aug 20207:00 amRNSAMRYT PRESENTING AT CANACCORD GENUITY CONFERENCE
6th Aug 202012:00 pmRNSAMRYT ANNOUNCES Q2 2020 RESULTS
29th Jul 20202:30 pmRNSResult of AGM
29th Jul 20207:00 amRNSAMRYT HOSTING KOL CALL ON EB DISEASE LANDSCAPE
20th Jul 20207:00 amRNSAMRYT TO ANNOUNCE Q2 RESULTS ON AUGUST 6, 2020
15th Jul 20208:00 amRNSEuronext Growth Dublin Notice
10th Jul 20207:00 amRNSExercise of Warrants & Issue of Ordinary Shares
8th Jul 20203:09 pmRNSAMRYT LISTED ON NASDAQ & CEO TO RING CLOSING BELL
30th Jun 20207:00 amRNSPOSTING OF ANNUAL REPORT AND NOTICE OF AGM
24th Jun 20207:00 amRNSForm F-1 publicly filed for impending US listing
4th Jun 20202:20 pmRNSDirector/PDMR Shareholding
3rd Jun 202011:30 amRNSDirector/PDMR Shareholding
3rd Jun 20207:00 amRNSAMRYT & SWIXX SIGN DISTRIBUTION DEAL FOR MYALEPTA
11th May 20207:00 amRNSQ1 2020 RESULTS
11th May 20207:00 amRNSFY 2019 RESULTS
7th May 20209:00 amRNSNotice of Results
7th May 20207:00 amRNSFILSUVEZ® CONFIRMED AS GLOBAL BRAND NAME FOR AP101
23rd Apr 20207:00 amRNSEASE CLINICAL STUDY UPDATE
25th Mar 20207:00 amRNSHolding(s) in Company
23rd Mar 20207:00 amRNSMarket Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.